Ignite Creation Date:
2025-12-24 @ 4:37 PM
Ignite Modification Date:
2026-06-15 @ 4:42 PM
Study NCT ID:
NCT01542866
Status:
COMPLETED
Last Update Posted:
2018-07-12
First Post:
2011-07-01
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A 16 Week Evaluation of the Novartis Health Management Tool (HMT) in Age Related Macular Degeneration (AMD)
Sponsor:
Novartis Pharmaceuticals
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Age Related Macular Degeneration (AMD) | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | ranibizumab | View |
| None | Age related Macular Degeneration | View |
| None | AMD | View |
| None | Health Management Tool | View |
| None | HMT | View |
| None | Best Corrected Visual Acuity | View |
| None | Investigator's Clinical Judgement of Change | View |
| None | Choroidal Neovascularization | View |
| None | Central Retinal Subfield Thickness | View |
| None | visual function self test | View |